| Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia IE Ahn, C Underbayev, A Albitar, SEM Herman, X Tian, I Maric, DC Arthur, ... Blood, The Journal of the American Society of Hematology 129 (11), 1469-1479, 2017 | 344 | 2017 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 298 | 2020 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 214 | 2018 |
| Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib I Ahn, T Jerussi, M Farooqui, M Tian, A Wiestner, J Gea-Banacloche Blood 128 (15), 1940-1943, 2016 | 169 | 2016 |
| Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines C Pleyer, MA Ali, JI Cohen, X Tian, S Soto, IE Ahn, EM Gaglione, ... Blood, The Journal of the American Society of Hematology 137 (2), 185-189, 2021 | 129 | 2021 |
| Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations IE Ahn, X Tian, A Wiestner New England Journal of Medicine 383 (5), 498-500, 2020 | 107 | 2020 |
| A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era HR Robinson, J Qi, EM Cook, C Nichols, EL Dadashian, C Underbayev, ... Blood, The Journal of the American Society of Hematology 132 (5), 521-532, 2018 | 98 | 2018 |
| Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model IE Ahn, X Tian, D Ipe, M Cheng, M Albitar, LC Tsao, L Zhang, W Ma, ... Journal of Clinical Oncology 39 (6), 576, 2021 | 88 | 2021 |
| Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib C Sun, P Nierman, EK Kendall, J Cheung, M Gulrajani, SEM Herman, ... Blood, The Journal of the American Society of Hematology 136 (1), 93-105, 2020 | 84 | 2020 |
| Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia E Tissino, D Benedetti, SEM Herman, E Ten Hacken, IE Ahn, KG Chaffee, ... Journal of Experimental Medicine 215 (2), 681-697, 2018 | 81 | 2018 |
| Temporal differential effects of proinflammatory cytokines on osteoclastogenesis SJ Moon, IE Ahn, H Jung, H Yi, J Kim, Y Kim, SK Kwok, KS Park, JK Min, ... International journal of molecular medicine 31 (4), 769-777, 2013 | 78 | 2013 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Targeting Bruton’s tyrosine kinase in CLL IE Ahn, JR Brown Frontiers in Immunology 12, 687458, 2021 | 59 | 2021 |
| Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib C Vitale, IE Ahn, M Sivina, A Ferrajoli, WG Wierda, Z Estrov, SN Konoplev, ... Haematologica 101 (6), e254, 2016 | 49 | 2016 |
| Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials JN Allan, T Shanafelt, A Wiestner, C Moreno, SM O’Brien, J Li, G Krigsfeld, ... British Journal of Haematology 196 (4), 947-953, 2022 | 44 | 2022 |
| Overcoming acquired epigenetic resistance to BTK inhibitors AL Shaffer III, JD Phelan, JQ Wang, DW Huang, GW Wright, M Kasbekar, ... Blood cancer discovery 2 (6), 630-647, 2021 | 32 | 2021 |
| Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with … A Albitar, W Ma, I DeDios, J Estella, I Ahn, M Farooqui, A Wiestner, ... Oncotarget 8 (11), 17936, 2017 | 32 | 2017 |
| Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL IE Ahn, N Basumallik, X Tian, S Soto, A Wiestner Blood, The Journal of the American Society of Hematology 133 (22), 2452-2455, 2019 | 29 | 2019 |
| Periarticular osteoporosis is a prominent feature in early rheumatoid arthritis: estimation using shaft to periarticular bone mineral density ratio SJ Moon, IE Ahn, SK Kwok, KS Park, JK Min, SH Park, HY Kim, JH Ju Journal of Korean Medical Science 28 (2), 287, 2013 | 29 | 2013 |
| Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del (17p) or TP53 … JN Allan, T Shanafelt, A Wiestner, C Moreno, SM O'Brien, E Braggio, E Liu, ... Blood 136, 23-24, 2020 | 28 | 2020 |
